Dr. Wagner is a clinical nephrologist. He is the Director of the Kidney Institute of New Mexico as well as being the acting Associate Chief of Research and Renal Section Chief for the VA in Albuquerque.
This is the second time Dr. Wagner has been on the podcast with his research team. In this episode we re-examine the mechanisms behind gadolinium retention and receive updates on new discoveries.
To fund Dr. Wagner’s work you can donate to the Kidney Institute of New Mexico at
https://www.unmfund.org/fund/unm-kidney-institute-of-new-mexico/
Links:
Reveal Pharmaceuticals, Gadolinium-free MRI contrast agents products.
http://www.revealpharma.com
The FDA adverse event reporting system
https://open.fda.gov/data/faers/
Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378745/
Dr. Wagner is a clinical nephrologist. He is the Director of the Kidney Institute of New Mexico as well as being the acting Associate Chief of Research and Renal Section Chief for the VA in Albuquerque.
This is the second time Dr. Wagner has been on the podcast with his research team. In this episode we re-examine the mechanisms behind gadolinium retention and receive updates on new discoveries.
To fund Dr. Wagner’s work you can donate to the Kidney Institute of New Mexico at
https://www.unmfund.org/fund/unm-kidney-institute-of-new-mexico/
Links:
Reveal Pharmaceuticals, Gadolinium-free MRI contrast agents products.
http://www.revealpharma.com
The FDA adverse event reporting system
https://open.fda.gov/data/faers/
Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378745/